Safety: what we know, what we dont What clinical trial safety reviews suggest The clinical safety review literature reports several reassuring signals: No meaningful increase in IGF-1 in monitored long-term studies (jofem.org) No clear negative effect on carbohydrate metabolism in testing described (contrast with full hGH) (jofem.org) No clear immunogenicity signal (e.g., anti-AOD antibodies) in the subset assessed in those trials (jofem.org) The major limitation: long-term real-world certainty is thin The problem with many peptides is not that everything is dangerousits that the certainty level is often lower than patients assume
By blocking NNMT, the compound is associated with preserved NAD+ levels and reduced fat storage, alongside improvements in cellular energy utilization and insulin sensitivity
The absorption rate is appropriate, the technique is simple, and it's far more comfortable than intramuscular injection
This program combines Semaglutide peptide therapy with a nutritional support, macro guidance and exercise routine to give you optimal results
If youre new to these shots, talk to your healthcare provider about what to expect and how often you might need them
Phase 4: AOD 9604 cycle break (week 17+) After 12-16 weeks of AOD 9604, discontinue it for a 4-week break while continuing tirzepatide